Arterys Cardio DL vs AVIEW LCS

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Arterys (now part of Tempus)
VS
by Coreline Soft Co.

AI Verdict

Tool A is specialized for detailed cardiac MRI analysis, focusing on automated ventricle segmentations and blood flow visualization. In contrast, Tool B targets lung cancer screening and cardiopulmonary assessment using low-dose CT scans, offering automated lung nodule detection, emphysema quantification, and coronary artery calcification scoring. While both leverage AI in radiology and touch upon cardiology, their primary imaging modalities and specific diagnostic applications are distinct.

Choose Arterys Cardio DL if…

Choose Arterys Cardio DL if your primary need is rapid, accurate, and automated analysis of cardiac MRI studies. This tool is ideal for cardiologists and radiologists seeking to streamline ventricle segmentation, quantify blood flow with 4D Flow, and perform quantitative delayed enhancement analysis to enhance diagnostic confidence in cardiac function.

View Arterys Cardio DL →

Choose AVIEW LCS if…

Choose AVIEW LCS if you require an integrated AI solution for comprehensive cardiopulmonary assessment from low-dose CT scans. This platform is best suited for practices focused on automated lung nodule detection, emphysema quantification, and coronary artery calcification scoring, providing a streamlined workflow for multiple critical diagnoses.

View AVIEW LCS →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Arterys Cardio DL AVIEW LCS
Pricing Unknown Contact for pricing
Deployment Cloud-based (SaaS), integrates with existing PACS or EHR, web-based zero-footprint viewer (Mac, PC, tablet, phone). [4, 7, 9, 13, 27] Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)
FDA Status 1 AI-estimated 1 AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Arterys Cardio DL

Tool A explicitly highlights 'editable automated contours,' which provides clinicians with crucial control and the ability to fine-tune AI outputs, enhancing trust and practical usability in a clinical workflow. Its cloud-based nature also ensures easy accessibility and rapid processing. While Tool B offers comprehensive automation and integration, the explicit emphasis on editable outputs in Tool A gives it a slight edge in user control.

Clinical Value

AVIEW LCS

Tool B offers a broader clinical utility by assessing multiple critical conditions (lung cancer, COPD, and coronary artery calcification) from a single low-dose CT scan, providing a more comprehensive cardiopulmonary assessment. This integrated approach can significantly enhance screening programs and provide a holistic view of patient health. Tool A, while highly effective in its specialized cardiac MRI domain, has a narrower focus.

Pricing & Value

Tie

Both tools require direct contact for pricing information, making a direct comparison of their cost or value proposition impossible based on the provided data. Without transparent pricing, it is difficult to determine which offers better financial value. Therefore, this dimension is a tie.

Enterprise Readiness

AVIEW LCS

Tool B demonstrates superior enterprise readiness due to its highly flexible deployment options, including cloud, hybrid, local hardware, and virtualized solutions, catering to diverse IT infrastructures and security requirements. Its explicit integration with PACS/RIS and third-party platforms further ensures seamless adoption into existing clinical workflows. Tool A is limited to cloud-based deployment.

Innovation

Arterys Cardio DL

Tool A claims to be 'the world's first internet platform for medical imaging,' indicating a pioneering role in bringing cloud-based AI to medical diagnostics, which was a significant innovation at its inception. While Tool B's integrated multi-disease assessment from a single scan is highly innovative for comprehensive screening, Tool A's foundational platform innovation holds a broader historical significance in the field.

Support & Docs

Tie

Both companies, Arterys and Coreline Soft, appear to offer standard customer support channels, including technical assistance and potentially training resources, as indicated by their corporate websites. However, the provided structured facts and general web searches do not offer sufficient granular detail on the quality, comprehensiveness of documentation, or responsiveness of support to definitively distinguish between the two.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Arterys Cardio DL AVIEW LCS
Name Arterys Cardio DL AVIEW LCS
Primary Focus Automated, editable ventricle segmentations for cardiac MRI analysis AI-powered solution for the detection and analysis of lung nodules, lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan
Company ARTERYS Coreline Soft Co.
Specific Analysis Type 1 Automated ventricle segmentations for cardiac MRI Automated lung nodule detection and analysis
Specific Analysis Type 2 4D Flow post-processing for blood flow visualization and quantification Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass)
Specific Analysis Type 3 Quantitative Delayed Enhancement analysis Emphysema quantification (LAA index)

Videos

Demos, reviews, and walkthroughs featuring Arterys Cardio DL and AVIEW LCS.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Arterys Cardio DL is an AI software focused on automated, editable ventricle segmentations for cardiac MRI analysis, aiming to reduce interpretation time and enhance diagnostic accuracy. AVIEW LCS is an AI-powered solution for the detection and analysis of lung nodules, offering integrated analysis of lung cancer, COPD, and coronary artery calcification from low-dose CT scans.
Arterys Cardio DL is designed for the analysis of cardiac MRI images. AVIEW LCS is utilized for the analysis of low-dose CT scans, specifically for lung and cardiopulmonary assessment.
Arterys Cardio DL provides automated ventricle segmentations, 4D Flow post-processing for blood flow visualization, and Quantitative Delayed Enhancement analysis for cardiac MRI. AVIEW LCS offers automated lung nodule detection and analysis, Lung-RADS classification, emphysema quantification, and coronary artery calcification (CAC) scoring from CT scans.
Arterys Cardio DL emphasizes vendor-agnostic compatibility. AVIEW LCS explicitly states integration with PACS/RIS and third-party platforms.
Arterys Cardio DL drastically reduces cardiac MRI interpretation time, offering rapid analysis in seconds compared to 30-60 minutes. AVIEW LCS aims to streamline radiology workflows and enhance diagnostic accuracy for lung cancer screening and cardiopulmonary assessment.
AI Tool Finder
AI-powered search. Results may not be comprehensive.